文献速递肿瘤 PET/CT核素与放射性配体治疗

成纤维细胞激活蛋白靶向PET显像在转移性去势抵抗性前列腺癌中的应用:与68Ga-PSMA及18F-FDG PET/CT的对比

Fibroblast Activation Protein-Targeted PET Imaging of Metastatic Castration-Resistant Prostate Cancer Compared With 68Ga-PSMA and 18F-FDG PET/CT.
PubMed 文献 · Clin Nucl Med · 2022-01-01

本文报道2例转移性去势抵抗性前列腺癌(mCRPC)患者,为评估PSMA靶向放射配体治疗资格行68Ga-PSMA PET/CT,因FDG阳性与低PSMA表达不一致提示侵袭性行为,进一步行18F-FDG PET/CT显示瘤内异质性,遂加做68Ga-FAPI-04 PET/CT评估FAP靶向治疗潜力。本报告强调FAP显像在mCRPC尤其肿瘤表型异质患者中的诊疗一体化潜力。

要点

  • mCRPC患者FDG阳性而PSMA低表达提示侵袭性行为和不良预后。
  • 18F-FDG PET/CT可显示mCRPC瘤内异质性。
  • 68Ga-FAPI-04 PET/CT可用于评估mCRPC的FAP靶向治疗潜力。

核心结论

  • FAP显像在mCRPC尤其肿瘤表型异质患者中具有诊疗一体化潜力。

研究设计与样本

  • 本文为2例mCRPC患者的病例报告,患者因评估PSMA靶向放射配体治疗资格行68Ga-PSMA PET/CT。

主要发现

  • 2例患者因FDG阳性与低PSMA表达不一致,进一步行18F-FDG PET/CT显示瘤内异质性。
  • 患者加做68Ga-FAPI-04 PET/CT以评估FAP靶向治疗潜力。

临床怎么用

  • 对FDG阳性而PSMA低表达的mCRPC患者,可考虑加做FAP靶向PET/CT评估FAP靶向治疗潜力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Herein we present 2 mCRPC (metastatic castration-resistant prostate cancer) patients who underwent 68Ga-PSMA PET/CT for PSMA-targeted radioligand therapy eligibility. Prior studies have noted aggressive clinical behavior and poor prognosis associated with discordant FDG positivity and low PSMA expression. Accordingly, the patients also underwent 18F-FDG PET/CT, which revealed intratumoral heterogeneity. Therefore, an additional PET/CT targeting fibroblast activation proteins (FAPs) using 68Ga-FAPI-04 was performed to assess the potential for an FAP-targeted therapy. This report highlights the theranostic potential of FAP imaging in mCRPC, particularly in patients with heterogeneous tumor phenotypes.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Isik EG, Has-Simsek D, Sanli O, et al. Fibroblast Activation Protein-Targeted PET Imaging of Metastatic Castration-Resistant Prostate Cancer Compared With 68Ga-PSMA and 18F-FDG PET/CT. Clin Nucl Med. 2022. PMID: 34392294. doi:10.1097/RLU.0000000000003837

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。